Acción LWACU LOCT WALK
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas LOCT WALK Nasdaq

Acciones

LWACU

US54015L3015

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
EFFECTOR Therapeutics : Accelaration/Increase of Financial Obligation Form 8 K
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
Top Midday Decliners
Sector Update: Health Care Stocks Advance Monday Afternoon
EFFECTOR Therapeutics to Shut Down Operations, Seeking Strategic Alternatives
EFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
EFFECTOR Therapeutics, Inc Appoints Craig R. Jalbert as CEO
EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as President, Treasurer and Secretary, and Sole Member of the Board
EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Health Care Down on Retreat From Risk -- Health Care Roundup
Top Midday Decliners
EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
EFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
Top Premarket Decliners
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
EFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
EFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
EFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
EFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción EFTR
  4. Acción LWACU
  5. Noticias LOCT WALK
  6. Otros idiomas